Ensifentrine Improves Lung Function in Chinese Patients With COPD: ENHANCE-CHINA Study
核心洞察
Ensifentrine, a dual PDE3 (搜索)/4 inhibitor, significantly improved lung function compared with placebo in Chinese patients with moderate to severe COPD over a 24-week trial.
The ENHANCE-CHINA study of 525 patients found improvements in FEV1 AUC0-12h held regardless of COPD severity or concomitant maintenance therapy.
Patients reported reduced dyspnea, improved respiratory symptoms and quality of life, with a trend toward delaying first exacerbation and fewer moderate-to-severe flare-ups.
Ensifentrine, a dual PDE3 (搜索)/4 inhibitor, significantly improved lung function in Chinese patients with moderate to severe chronic obstructive pulmonary disease (搜索) (COPD) compared with placebo, according to the ENHANCE-CHINA study published in the CHEST Journal. The trial, which enrolled 525 patients between March 2023 and March 2025, found that the therapy was both highly efficacious and well-tolerated, with benefits that held true regardless of disease severity or concomitant maintenance treatment.
COPD is a progressive respiratory illness that affects around 100 million individuals in China. Despite typical inhalation treatments, many patients continue to experience symptoms, prompting the development of new medications. Ensifentrine has shown considerable bronchodilator and anti-inflammatory activity in Western populations, increasing lung function and lowering exacerbations. However, because medication reactions differ by ethnicity and clinical data for Chinese populations remain scarce despite comparable pharmacokinetics, the ENHANCE-CHINA research was designed to assess ensifentrine's effectiveness and safety specifically in Chinese COPD patients.
Study Design and Endpoints
Participants with moderate to severe symptomatic COPD were recruited and randomly assigned over a 24-week period to either the ensifentrine group or the placebo group in a 5:3 ratio. Participants were divided into groups based on their smoking status and maintenance treatment.
The main outcome was improvement in lung function as determined by the FEV1 area under the curve at 0 to 12 hours. Quality of life, symptoms, and exacerbations served as additional end goals.
Efficacy Results
In an examination of 525 patients, over half of whom were using concomitant maintenance drugs, ensifentrine was shown to be highly efficacious compared with placebo. Over the course of a 12-hour period, the therapy considerably increased patients' lung capacity, and these advantages held true regardless of the patients' COPD severity or whether they were receiving additional maintenance treatments.
Patients using ensifentrine reported general improvements in their respiratory symptoms and quality of life, as well as significantly reduced dyspnea and improved lung function. Additionally, the drug tended to postpone a patient's initial exacerbation and lessen the frequency of moderate-to-severe flare-ups.
Safety Profile
Crucially, ensifentrine users and placebo users experienced identical rates of side events, suggesting a similar safety profile between the treatment and control groups.
Overall, ensifentrine significantly improved lung function in Chinese subjects with moderate to severe COPD when compared with placebo. Furthermore, ensifentrine was found to enhance symptoms and quality of life, as well as show a trend toward reducing exacerbations, which is consistent with prior worldwide research.